With emerging treatment options and technological advances that make detection and monitoring more precise, timely and easier, wet age-related macular degeneration continues to be a vibrant area of research and innovation.
The path is not always smooth: The risk for severe inflammatory events cooled down the early enthusiasm for Beovu (brolucizumab, Novartis), and concerns about septum dislodgement and potential adverse events led Genentech to voluntarily recall Susvimo (ranibizumab injection).
However, progress and innovation never come without challenges, and the landscape for wet AMD today